Scarica l'app Stockscreener
246.20
0.98%
2.40
Dopo l'orario di chiusura:
246.77
0.57
+0.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie Inc Stock (ABBV) Moved Up by 3.35% on Jul 28: A Full Analysis - TradingKey
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates? - TradingView
AbbVie Inc. (ABBV) Stock Forecasts - Yahoo Finance
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees - The Motley Fool
Barclays Adjusts AbbVie PT to $300 From $275, Maintains Overweight Rating - marketscreener.com
Should You Buy AbbVie Stock Hand Over Fist Before July 31? - The Motley Fool
AbbVie Seeks Block On Alkem Generic Constipation Drug - Law360
Former AbbVie, Amgen exec Severino takes the reins at Sarepta - FirstWord Pharma
Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter - Fierce Pharma
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO - BioPharma Dive
AbbVie Researcher Dr. Jan Stoehr Outlines Use of Biomarkers to Target Parkinson’s Disease Progression - geneonline.com
Sarepta names former Abbvie president as CEO as Ingram retires - Reuters
Sarepta names former AbbVie R&D exec Michael Severino as next CEO - BioSpace
AbbVie stock hits all-time high of 261.71 USD - Investing.com
Is AbbVie Stock a Buy After Its $10.9 Billion Apogee Bet - TIKR.com
How Abbvie Inc. (ABBV) Affects Rotational Strategy Timing - Stock Traders Daily
AbbVie Inc. (ABBV) Stock Analysis: A Healthcare Giant With A Promising 3.25% Upside - DirectorsTalk Interviews
ABBV|AbbVie Inc|Price:265.610|Chg%:+8.700 - TradingKey
AbbVie Inc Agencies, 2026 - OpenSecrets
Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson? - The Motley Fool
AbbVie stock steadies as investors weigh Humira erosion against Skyrizi and Rinvoq growth - Ad-hoc-news.de
AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback - Yahoo Finance
AbbVie stock trades steadily as Humira erosion meets Skyrizi and Rinvoq growth - AD HOC NEWS
Should You Pay Attention To AbbVie Stock's Momentum? - Trefis
AbbVie stock may move 4.2% on July 31 earnings report By Investing.com - Investing.com Nigeria
AbbVie stock may move 4.2% on July 31 earnings report - Investing.com
AbbVie: A Dividend Fortress At An Appealing Price Tag - Seeking Alpha
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
AbbVie (ABBV) and Genmab's Epcoritamab Fails Key Trial Endpoint - GuruFocus
AbbVie, Genmab post trial setback for lymphoma drug (ABBV:NYSE) - Seeking Alpha
CNBC ‘Final Trades’: Netflix, AbbVie, Cerebras SystemsNetflix (NASDAQ:NFLX), CrowdStrike Holdings (NAS - Benzinga
AbbVie stock trades steadily as investors weigh Skyrizi and Rinvoq growth against Humira erosion - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Thermo Fisher (TMO) and AbbVie (ABBV) - The Globe and Mail
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - Investing News Network
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Epcoritamab U.S. Lymphoma Trial Does Not Meet Survival Endpoint - Stock Titan
AbbVie: Bright Future, But Already Priced In (NYSE:ABBV) - Seeking Alpha
Donald TrumpABBVIE INC COM UNSOLICITED Trump Trade on Mar. 25, 2026 - Quiver Quantitative
AbbVie stock holds near record levels after second-quarter results - Ad-hoc-news.de
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Total equity of AbbVie, Inc. – BCS:ABBV0 - TradingView
AbbVie Sues Galderma Over Patented Dermal Filler Syringe Designs - Bloomberg Law News
Will AbbVie's Oncology Franchise Remain Under Pressure in Q2? - TradingView
Canaccord Genuity Adjusts Price Target on AbbVie to $282 From $273, Maintains Buy Rating - marketscreener.com
Canaccord raises Abbvie stock price target to $282 on growth outlook - Investing.com
ABBV Maintains Buy Rating -- Price Target Raised to $282 by Cana - GuruFocus
ETFs Investing in AbbVie, Inc. Stocks - TradingView
How Investors May Respond To AbbVie (ABBV) Securing EU Approval For Short-Acting Boey Aesthetic Toxin - Yahoo Finance
3 Reasons to Buy AbbVie Stock Like There's No Tomorrow - The Motley Fool
EBIT per share of AbbVie, Inc. – BCS:ABBVCL1 - TradingView
AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Enterprise value of AbbVie, Inc. – BCS:ABBV0 - TradingView
AbbVie Stock Zigs When The Market Zags - Trefis
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):